MADE Trial: Minocycline in Alzheimer’s Disease Efficacy trial | C4C

Alzheimer’s disease (AD) is a major public health issue and the imperative to discover and develop treatments that can stop or at least delay disease progression is clear. None of the three licensed drug treatments available for mild AD have been shown to affect progression of the illness. There is a substantial body of evidence to indicate that minocycline may be neuroprotective in neurodegenerative diseases such as AD and Minocycline is arguably the most promising off-patent candidate for AD modification that is not currently in trials and is cheap and well tolerated.